Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan

Core Viewpoint - Revolution Medicines Inc. experienced a significant decline in stock price following the cancellation of acquisition talks by Merck, which was seeking to acquire the company for $28 billion to $32 billion [2][4]. Group 1: Stock Performance - Revolution Medicines' stock fell by 16.91% to close at $97.78 after investors reacted to the news of Merck's withdrawal from acquisition negotiations [1]. - The company was highlighted as one of the worst performers in the market on that day [1]. Group 2: Acquisition Talks - Merck terminated discussions with Revolution Medicines due to disagreements over company valuation [2]. - The proposed acquisition was valued between $28 billion and $32 billion [2]. Group 3: Product Development - Revolution Medicines is advancing a pipeline of experimental medicines targeting RAS, which is crucial in treating difficult cancers [2]. - The company received a breakthrough designation from the FDA for its RAS(ON) G12D-selective inhibitor, zoldonrasib, aimed at treating specific lung cancer patients [3]. - Clinical trial results for zoldonrasib have shown a robust clinical profile, including promising antitumor activity and acceptable safety [4].